Treatment Options for Sexual Dysfunction in Patients with Chronic Kidney Disease
Open Access
- 1 June 2010
- journal article
- review article
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 5 (6) , 985-995
Abstract
Background and objectives: Sexual dysfunction is very common in patients with chronic kidney disease (CKD), but treatment options are limited. The benefits and harms of existing interventions for treatment of sexual dysfunction were assessed in patients with CKD. Design, setting, participants, & measurements: MEDLINE (1966 to December 2008), EMBASE (1980 to December 2008), and the Cochrane Trial Registry (Issue 4 2008) were searched for parallel and crossover randomized and quasi-randomized trials. Treatment effects were summarized as mean differences (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI) using a random effects model. Results: Fourteen trials (328 patients) were included. Phosphodiesterase-5 inhibitors (PDE5i) compared with placebo significantly increased the overall International Index of Erectile Function-5 (IIEF-5) score (three trials, 101 patients, MD 1.81, 95% CI 1.51 to 2.10), all of its individual domains, and the complete 15-item IIEF-5 (two trials, 80 patients, MD 10.64, 95% CI 5.32 to 15.96). End-of-treatment testosterone levels were not significantly increased by addition of zinc to dialysate (two trials, 22 patients, SMD 0.19 ng/dl, 95% CI −2.12 to 2.50), but oral zinc improved end-of-treatment testosterone levels. There was no difference in plasma luteinizing and follicle-stimulating hormone level at the end of the study period with zinc therapy. Conclusions: PDE5i and zinc are promising interventions for treating sexual dysfunction in CKD. Evidence supporting their routine use in CKD patients is limited. There is an unmet need for studying interventions for male and female sexual dysfunction in CKD considering the significant disease burden.Keywords
This publication has 52 references indexed in Scilit:
- Hormonal Testing and Pharmacologic Treatment of Erectile Dysfunction: A Clinical Practice Guideline From the American College of PhysiciansAnnals of Internal Medicine, 2009
- Oral Phosphodiesterase-5 Inhibitors and Hormonal Treatments for Erectile Dysfunction: A Systematic Review and Meta-analysisAnnals of Internal Medicine, 2009
- The association of higher depressive symptoms and sexual dysfunction in male haemodialysis patientsNephrology Dialysis Transplantation, 2007
- Treatment of Erectile Dysfunction With Sildenafil Citrate in Renal Allograft Recipients: A Randomized, Double-Blind, Placebo-Controlled, Crossover TrialAmerican Journal of Kidney Diseases, 2006
- Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reportsInternational Journal Of Impotence Research, 2004
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002
- Prevalence and determinants of erectile dysfunction in hemodialysis patientsKidney International, 2001
- Zinc: A possible role in the reversal of uremic impotenceSexuality and Disability, 1982
- ABSENCE OF A THERAPEUTIC EFFECT OF ZINC IN THE SEXUAL DYSFUNCTION OF HqMODIALYSED PATIENTSThe Lancet, 1980
- REVERSAL OF URÆMIC IMPOTENCE BY ZINCThe Lancet, 1977